loading...| Preferred Name | alectinib | |
| Synonyms |
CH5424802 UNII-LIJ4CT1Z3Y Alecensa RG7853 RO5424802 5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo- AF-802 anaplastic lymphoma kinase inhibitor CH5424802 ALK inhibitor CH5424802 AF802 |
|
| Definitions |
An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C101790" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C101790" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000733572 |
|
| altLabel |
CH5424802 UNII-LIJ4CT1Z3Y Alecensa RG7853 RO5424802 5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo- AF-802 anaplastic lymphoma kinase inhibitor CH5424802 ALK inhibitor CH5424802 AF802 |
|
| CAS Registry |
1256580-46-7 |
|
| cui |
C3642266 C3853922 C4060047 C3640218 C3640219 C3853921 |
|
| DATE FIRST PUBLISHED |
2012-05-02 |
|
| Date last modified |
2015-12-14 |
|
| definition |
An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C101790" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C101790" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C101790 |
|
| notation |
CDR0000733572 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
alectinib |
|
| tui |
T109 T121 |